Therapeutic Area | MeSH |
---|---|
infections | D007239 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
SIRTURO | Johnson & Johnson | N-204384 RX | 2012-12-28 | 2 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
sirturo | New Drug Application | 2023-10-17 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
multidrug-resistant tuberculosis | EFO_0007381 | D018088 | — |
mycobacterium infections | — | D009164 | A31.9 |
Expiration | Code | ||
---|---|---|---|
BEDAQUILINE FUMARATE, SIRTURO, JANSSEN THERAP | |||
2027-05-27 | ODE-307 | ||
2026-08-09 | ODE-251 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multidrug-resistant tuberculosis | D018088 | EFO_0007381 | — | — | 11 | 12 | 3 | 3 | 23 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 6 | 13 | 6 | — | 4 | 25 |
Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | — | 19 | 10 | — | — | 24 |
Extensively drug-resistant tuberculosis | D054908 | — | — | — | 4 | 6 | — | — | 6 |
Bacterial infections | D001424 | — | A49 | — | — | 2 | — | — | 2 |
Leprosy | D007918 | EFO_0001054 | A30 | — | 1 | 1 | — | — | 2 |
Lung diseases | D008171 | HP_0002088 | J98.4 | — | 1 | 1 | — | — | 1 |
Gram-positive bacterial infections | D016908 | — | — | — | — | 1 | — | — | 1 |
Mycobacterium infections | D009164 | — | A31.9 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 2 | 2 | — | — | 2 | 5 |
Hiv | D006678 | — | O98.7 | 3 | 2 | — | — | — | 4 |
Infections | D007239 | EFO_0000544 | — | — | 1 | — | — | — | 1 |
Multibacillary leprosy | D056006 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Bedaquiline |
INN | bedaquiline |
Description | Bedaquiline is a quinoline-based antimycobacterial drug used (as its fumarate salt) for the treatment of pulmonary multi-drug resistant tuberculosis by inhibition of ATP synthase, an enzyme essential for the replication of the mycobacteria. It has a role as an antitubercular agent and an ATP synthase inhibitor. It is a member of quinolines, a member of naphthalenes, an organobromine compound, an aromatic ether, a tertiary alcohol and a tertiary amino compound. It is a conjugate base of a bedaquiline(2+). |
Classification | Small molecule |
Drug class | antibiotics, diarylquinoline structure |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12 |
PDB | — |
CAS-ID | 843663-66-1 |
RxCUI | — |
ChEMBL ID | CHEMBL376488 |
ChEBI ID | 72292 |
PubChem CID | 5388906 |
DrugBank | DB08903 |
UNII ID | 78846I289Y (ChemIDplus, GSRS) |